Highbridge Capital Management LLC Adverum Biotechnologies, Inc. Transaction History

Highbridge Capital Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 15, 2019	SELL	$3.03 - $6.02 $78,870 - $156,700	-26,030 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$2.87 - $5.92 $355,793 - $733,902	-123,970 Reduced 82.65%	26,030 $82,000
Q3 2018 Nov 13, 2018	SELL	$4.5 - $7.6 $6.8 Million - $11.5 Million	-1,511,986 Reduced 90.97%	150,000 $908,000
Q2 2018 Aug 14, 2018	SELL	$5.3 - $6.9 $2.32 Million - $3.02 Million	-438,014 Reduced 20.86%	1,661,986 $8.81 Million
Q1 2018 May 15, 2018	SELL	$3.65 - $7.95 $730,000 - $1.59 Million	-200,000 Reduced 8.7%	2,100,000 $12.2 Million
Q4 2017 Feb 14, 2018	BUY	$2.85 - $3.95 $6.46 Million - $8.95 Million	2,266,830 Added 6833.98%	2,300,000 $8.05 Million
Q2 2017 Aug 14, 2017	BUY	N/A	33,170	33,170 $83,000

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Highbridge Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Highbridge Capital Management LLC with notifications on news.